Table 2.
Comparison of baseline characters of 122 patients with high risk of recurrence concerning PD-L1 level.
| PD-L1 (−) | PD-L1 (+) | p | |
|---|---|---|---|
| N = 79 | N = 43 | ||
| Age | 52.6 + 12.2 | 52.2 + 12.2 | 0.857 |
| Age ≥55 (%) | 31 (39.2) | 17 (39.5) | 1.000 |
| Male (%) | 74 (93.7) | 38 (88.4) | 0.321 |
| Max tumor size | 7.1 + 2.9 | 7.5 + 4.2 | 0.500 |
| Size ≥5 cm (%) | 63 (79.7) | 31 (72.1) | 0.372 |
| Multiple tumors (%) | 20 (25.3) | 17 (39.5) | 0.148 |
| Vascular invasion (VI) | |||
| Macro-VI (%) | 16 (20.3) | 13 (30.2) | 0.267 |
| Micro-VI (%) | 49 (62) | 21 (48.8) | 0.183 |
| BCLC | |||
| 0/A | 40 (50.6) | 16 (37.2) | 0.306 |
| B | 23 (29.1) | 14 (32.6) | |
| C | 16 (20.3) | 13 (30.2) | |
| TNM Stage (I/II/III) | 18/28/33 | 11/13/19 | 0.838 |
| TB | 17.5 + 9.9 | 17.2 + 10.7 | 0.859 |
| ALT | 64.6 + 79.7 | 53.5 + 63.8 | 0.433 |
| AST | 75.4 + 94 | 79.6 + 210.2 | 0.879 |
| ALB | 42.4 + 7.4 | 42.3 + 5.3 | 0.964 |
| Cirrhosis | 49 (62) | 28 (65.1) | 0.845 |
| Poor Differentiation (%) | 44 (55.7) | 15 (34.9) | 0.037 |
| HBV (%) | 75 (94.9) | 36 (83.7) | 0.333 |
| Child–Pugh grade A (%) | 6 (7.6) | 3 (7) | 1.000 |
| AFP ≥200 (%) | 36 (45.6) | 19 (44.2) | 1.000 |
PD-L1, programmed death-ligand 1; BCLC, Barcelona Clinic Liver Cancer; TNM, tumor-node-metastasis; TB, total bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; ALB, albumin; HBV, hepatitis B virus; AFP, alpha fetoprotein.